In this episode, Dr. Ziad Obermeyer joins Chip to talk about AI bias in patient management, including how far the health care industry has come since his groundbreaking research that revealed alarming biases in a widely used algorithm that underestimated the health needs of Black patients.
Apogee Therapeutics brings AbbVie a long-acting antibody ready for Phase 3 testing in atopic dermatitis, also called eczema. This therapy’s pipeline in a product potential includes respiratory conditions such as asthma — as a monotherapy and as part of novel drug combinations. The post AbbVie’s $11B Apogee Acquisition Brings an Eczema Drug With an Edge…
Eli Lilly made good on its threat to withhold 340B drug discounts from hospitals that refused to submit claims data. Hospital groups are calling the policy unlawful, arguing that the company has no legal authority to create its own compliance requirements for a federal program. The post Hospitals Cry Foul After Eli Lilly Withholds 340B…
Abarca Health and LucyRx plan to combine to build a larger independent PBM serving more than 9 million members. The post Abarca Health and LucyRx to Combine to Scale Independent PBM Model appeared first on MedCity News.
Many at-risk hospitals are burdened with debt and lack sufficient assets, according to the Center for Healthcare Quality and Payment Reform
Diane Hunt, M.D., chief health information officer, discusses treating the transition as a health system project rather than just an IT project
Alternative health plan designs represent much more than a passing trend. They are actively testing long-standing assumptions about how benefits should be structured, delivered, and experienced. The post Alternative Health Plan Designs Are Reshaping Employer Benefits appeared first on MedCity News.
For governments and health systems, monoclonal antibodies represent not just another drug class, but a strategic shift toward precision prevention. The post Passive Immunization: The Expanding Role of Monoclonal Antibodies in Preventive Medicine appeared first on MedCity News.
We’re entering uncharted territory if bad actors can both launch zero-days and exploit unaddressed backdoors with new efficiency. This is why teams need to unify their network structure and better forecast what they’re up against. The post Preparing Healthcare Networks For The Vulnerability Flood appeared first on MedCity News.
Bionyra Pharma’s pipeline includes two drugs that target the signaling protein TL1A, alone and as part of a combination approach to treat inflammatory disorders. The startup’s launch makes it a contender in an emerging drug class that includes late-clinical assets from Merck, Roche, and partners Sanofi and Teva Pharmaceuticals. The post Inflammation Startup Bionyra Launches…